Viatris Inc. (VTRS)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 4
Buy limit 20.28 at the 2026-11-10 swing-low support (20.26) inside an intact uptrend — price above SMA20/50/200, EMA9/21 and DEMA14, ADX14 34.4 rising, MACD 0.76 above signal 0.58 — after the 2026-11-12 rejection at a 52-week high 21.20. Stop 19.71 (Change-A 1.0xATR floor, also beneath the 19.90 swing low), targets 21.42 / 22.28, R/R 2.00. No earnings and no gating dividend inside the 2026-12-07 horizon; the buy-stop breakout alternative at 21.25 above the settled 21.20 high was considered and rejected — it clears the floor at R/R 1.50 but pays up into a rejection day for less reward than the pullback.
Company overview
Viatris Inc. is a global pharmaceutical company operating across four geographic divisions: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers a wide range of pharmaceutical products, including branded and generic drugs, biosimilars, and active pharmaceutical ingredients, targeting various therapeutic areas such as oncology, immunology, and endocrinology. The company also provides health management services and distributes its products globally through a diverse network.
Fundamental
fairViatris has strong cash flow and reduced debt but faces declining revenue and regulatory challenges.
Mixed: Viatris generates roughly $2B+ of annual free cash flow, has cut net debt by about $11B since 2021, holds gross leverage at 2.9x adjusted EBITDA inside its target range, and raised 2026 guidance — but revenue is in a five-year decline, GAAP earnings swing on goodwill impairments and purchase-accounting amortization, two Indian plants are under FDA enforcement, and both DCF models sit below the current share price.
Sentiment
fairSentiment is mixed with positive earnings momentum offset by regulatory concerns.
Dominant catalysts are the rewarded Q3 2026 print (announced, 2026-11-05: adjusted EPS $0.71 beat, 2026 guidance midpoints raised across all metrics) and the pending all-cash Pacira BioSciences acquisition (announced, tender offer expiring 2026-11-16, close expected end-November), both of which the in-window tape scored net-positive (earnings items +0.45/+0.35/+0.30 with no negative item; deal announcement items +0.40/+0.40). The sentiment delta is flat (polarity_score ≈ +0.22 baseline → +0.21 scoring, both windows measured), and a fresh bearish FDA/Nashik manufacturing overhang (Official Action Indicated classification plus voluntary suspension, per the 2026-11-05 10-Q) makes the catalyst map genuinely two-sided, so a moderate red-flag cap for conflicting catalysts applies while the severe screen is clear (no going-concern, no auditor change, no distress-linked dilution — Pacira is funded from cash and short-term borrowings).
Technical
goodViatris is in a stacked uptrend with a short-term pullback entry opportunity.
Bullish stacked uptrend with a short-term pullback entry. Price 20.67 sits above the SMA20 (19.16), SMA50 (18.03), SMA200 (16.20), EMA9 (20.08), EMA21 (19.29), WMA9 (20.29), WMA21 (19.54) and DEMA14 (20.56), with ADX14 at 34.43 rising monotonically from 22.98 ten sessions ago — because price is above every key average, that ADX read is uptrend STRENGTH, not a downtrend. MACD is positive and above signal (line 0.76 vs signal 0.58, histogram +0.19) and RSI14 69.07 / Williams %R -17.15 confirm momentum without breakdown. Two marks are soft: price is below TEMA14 (20.86) and below the 20.89 daily VWAP, because the 2026-11-12 session tagged a 52-week high at 21.20 and closed at 20.67 (-1.81%), 0.02 off its low — a rejection candle after a five-session, +13.5% run from the 18.64 11-03 low. That rejection is the one weak signal, and it argues for bidding a pullback rather than chasing a fresh breakout, hence score 4 rather than 5. The chosen plan is a pullback_to_support limit at 20.28 into the 2026-11-10 swing low 20.26, inside an intact uptrend and above the rising EMA9 20.08. Risk is 0.57 = exactly 1.0 x ATR14 on the Change-A floored stop 19.71, which also sits beneath the 19.90 2026-11-09 swing low; R/R 2.00 against target1 21.42. All Step-00 gates pass: price 20.67 under the $25 ceiling, fundamentalScore 3 and qualitativeScore 3 clear their floors, avgDollarVolume20 $187.2M and recent 3-session ~$186.4M clear both liquidity floors, max overnight gap 0.90% clears the 5% gate, ATR14 is 2.76% of price (above the 1.0% floor and in the 0.5xATR minimum-risk tier), dataAsOf 2026-11-12 is one trading day behind the run date, and the 15-trading-day window through 2026-12-07 contains no confirmed earnings and only a 0.58% dividend ex-date.
You’re looking at 2026-11-13 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

